{
    "clinical_study": {
        "@rank": "97283", 
        "arm_group": [
            {
                "arm_group_label": "GS-7977 and Ribavirin", 
                "arm_group_type": "Active Comparator", 
                "description": "48 weeks of GS 7977 400 mg QD + RBV (1000 or 1200 mg/day) BID"
            }, 
            {
                "arm_group_label": "24wk observation then 7977 and Ribavirin", 
                "arm_group_type": "Active Comparator", 
                "description": "24 weeks of Observation, then 48 weeks GS 7977 QD + RBV (1000 or 1200 mg/day) BID"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy\n      of GS-7977 and Ribavirin Administered for 48 weeks in Patients Infected with Chronic HCV\n      with Cirrhosis and Portal Hypertension with or without Liver Decompensation. Approximately\n      50 subjects (25 per group) will be randomized (1:1) to either receive study drug for 48\n      weeks or take part in an untreated observational arm for the first 24 weeks followed by\n      study drug for another 48 weeks."
        }, 
        "brief_title": "GS-7977 and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hepatitis C", 
            "Cirrhosis", 
            "Portal Hypertension", 
            "With or Without Liver Decompensation"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C", 
                "Hypertension", 
                "Hypertension, Portal", 
                "Liver Cirrhosis", 
                "Fibrosis", 
                "Liver Failure"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chronic infection with Hepatitis C with HCV RNA > 1000 IU/mL\n\n          -  Subjects with cirrhosis with Child-Pugh score < 10.\n\n          -  esophageal or gastric varices on endoscopy within 6 months prior to or at screening\n\n          -  Hepatic Venous Pressure Gradient (HVPG)  > 6 mmHg\n\n          -  Body mass index (BMI) >/= 18 kg/m2\n\n          -  Na\u00efve to all nucleotides/nucleoside treatments for chronic HCV infection\n\n        Exclusion Criteria:\n\n          -  Have any serious or active medical or psychiatric illness which, in the opinion of\n             the investigator, would interfere with subject treatment, assessment, or compliance\n\n          -  HIV or chronic hepatitis B virus (HBV) infection (HBsAg positive)\n\n          -  Alpha-fetoprotein (AFP) > 50 unless negative imaging for hepatic masses within the\n             last 6 months or during screening\n\n          -  Refractory ascites as defined by requiring paracentesis > twice within 1 month prior\n             to screening\n\n          -  Active variceal bleeding within 6 months of screening\n\n          -  Expected survival of < 1 year\n\n          -  History of hepatorenal, or hepatopulmonary syndrome.\n\n          -  Evidence of renal impairment (CrCl < 50 mL/min)\n\n          -  History of major organ transplantation, including liver transplant."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 12, 2012", 
        "has_expanded_access": "Yes", 
        "id_info": {
            "nct_id": "NCT01687257", 
            "org_study_id": "GS-US-334-0125"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "GS-7977 and Ribavirin", 
                    "24wk observation then 7977 and Ribavirin"
                ], 
                "intervention_name": "GS-7977", 
                "intervention_type": "Drug", 
                "other_name": "sofosbuvir"
            }, 
            {
                "arm_group_label": [
                    "GS-7977 and Ribavirin", 
                    "24wk observation then 7977 and Ribavirin"
                ], 
                "intervention_name": "Ribavirin", 
                "intervention_type": "Drug", 
                "other_name": "RBV"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ribavirin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newtown", 
                        "country": "Australia", 
                        "state": "New South Wales"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leclerc", 
                        "country": "France", 
                        "state": "Clichy"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Grafton", 
                        "country": "New Zealand", 
                        "state": "Auckland"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Majadahonda", 
                        "country": "Spain", 
                        "state": "Madrid"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "France", 
                "New Zealand", 
                "Spain"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 48 Weeks in Patients Infected With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Sustained virologic response 12 weeks after discontinuation of therapy (SVR12 defined as HCV RNA < lower limit of quantification [LLoQ] 12 weeks after last dose of study drug).", 
            "measure": "Sustained virologic response 12 weeks after discontinuation of therapy.", 
            "safety_issue": "No", 
            "time_frame": "12 weeks after discontinuation of therapy (SVR12)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01687257"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Determine the effect of 48 weeks of treatment on portal pressure as measured by Hepatic Venous Pressure Gradient (HVPG) measurements", 
                "measure": "Change in Hepatic Venous Pressure Gradient (HVPG) measurements", 
                "safety_issue": "No", 
                "time_frame": "Baseline and after 48 weeks of treatment"
            }, 
            {
                "description": "Assess safety laboratory tests and the number, frequency and severity of adverse events through 30 days post last dose of study drug", 
                "measure": "Frequency and severity of adverse events", 
                "safety_issue": "No", 
                "time_frame": "Safety and Tolerability on treatment and 30 days post last dose"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}